ReviewCancers2022
New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06444607 (HEPHESTOS - Hereditary Pheochromocytoma Assessment of Tumour Immunologies), which is not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
HEPHESTOS - Hereditary Pheochromocytoma Assessment of Tumour Immunologies
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Total adrenalectomy versus subtotal adrenalectomy for bilateral pheochromocytoma: meta-analysis.BJS open · 2023Pooled it
- Incidental finding of a cardiac paraganglioma following ischemic stroke: A case report.Radiology case reports · 2026Article
- Incidental discovery of a non-secreting bladder paraganglioma: A case report.Urology case reports · 2026Article
- Five Advances in the Last 50 Years That Have Impacted Endocrine Surgery.World journal of surgery · 2026Review
- The GAPP Aggressivity Score Correlates with Total Enriched Somatic Variant Burden in Sporadic Pheochromocytoma-A Pilot Study.Cancers · 2026Article
- Effects of catecholamines on bone and mineral metabolism in patients with pheochromocytoma and paraganglioma.The Journal of clinical endocrinology and metabolism · 2026Review
- From Tissue Architecture To Genetic Signature: Artificial intelligence-based Analysis of Reticulin Framework and Clinical Variables Predicts Molecular Cluster in Paragangliomas.Endocrine pathology · 2026Article
- Belzutifan for HIF2A-Related Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026Article
- Pathogenic MAX Variant in Bilateral Adrenal Paragangliomas: The Dilemma of Cortical-Sparing Surgery.Cureus · 2025Article
- Presurgical Succinate MetAstatic Risk Tool (P-SMART) in Paragangliomas.Endocrine pathology · 2025Article
- Rapid generation of a sdhb loss-of-function zebrafish model for secreting pheochromocytomas and paragangliomas.NPJ genomic medicine · 2025Article
- Prediction of Metastasis in Paragangliomas and Pheochromocytomas Using Machine Learning Models: Explainability Challenges.Sensors (Basel, Switzerland) · 2025Article
- Approach to the Management of Gastrointestinal Manifestations in Patients With Phaeochromocytoma and Paraganglioma.Clinical endocrinology · 2025Article
- Bilateral Pheochromocytoma with a Novel Pathogenic Variant in the MAX gene: A Case Report.Journal of the ASEAN Federation of Endocrine Societies · 2025Article
- Current Strategies for Managing Pheochromocytoma and Paraganglioma in Children and Adolescents.Medical science monitor : international medical journal of experimental and clinical research · 2025Review
- Perioperative Management Challenges in Silent Pheochromocytoma: A Case Report and Literature Review.Clinical case reports · 2025Article
- Editorial: Advances in diagnostics and management of adrenal tumors.Frontiers in endocrinology · 2025Article
- Exploring the critical role of SDHA in breast cancer proliferation: implications for novel therapeutic strategies.American journal of translational research · 2025Article
- Neuroendocrine Tumors: Germline Genetics and Hereditary Syndromes.Current treatment options in oncology · 2025Review
- Genetic landscape of Romanian PPGLs.Journal of cellular and molecular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare neuroendocrine tumors that arise from chromaffin cells. PHEOs arise from the adrenal medulla, whereas PGLs arise from the neural crest localized outside the adrenal gland. Approximately 40% of all cases of PPGLs (pheochromocytomas/paragangliomas) are associated with germline mutations and 30-40% display somatic driver mutations. The mutations associated with PPGLs can be classified into three groups. The pseudohypoxic group or cluster I includes the following genes:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.